EZH2, an epigenetic driver of prostate cancer
- First Online:
- Cite this article as:
- Yang, Y.A. & Yu, J. Protein Cell (2013) 4: 331. doi:10.1007/s13238-013-2093-2
The histone methyltransferase EZH2 has been in the limelight of the field of cancer epigenetics for a decade now since it was first discovered to exhibit an elevated expression in metastatic prostate cancer. It persists to attract much scientific attention due to its important role in the process of cancer development and its potential of being an effective therapeutic target. Thus here we review the dysregulation of EZH2 in prostate cancer, its function, upstream regulators, downstream effectors, and current status of EZH2-targeting approaches. This review therefore provides a comprehensive overview of EZH2 in the context of prostate cancer.